Friday, December 25, 2020

USFDA informs Biocon Biologics, Mylan of deferred action on Avastin biosimilar license application

USFDA informs Biocon Biologics, Mylan of deferred action on Avastin biosimilar license application Biocon Biologics Ltd and Mylan, a subsidiary of Viatris Inc, have been informed by the US Food and Drug Administration (USFDA) of a deferred action on the BLA for MYL-1402O, a proposed biosimilar to Avastin (bevacizumab), Biocon said in a regulatory filing.

from Moneycontrol Business News https://ift.tt/38Dx4qO
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

European shares log weekly losses on Iran war-linked inflation woesdrop

European markets experienced a significant downturn, with the STOXX 600 index sliding due to escalating energy inflation fears stemming from...